Pfizer Announces SUTENT Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors

Pfizer Inc.

announced today that the U.S. Food and Drug Administration has approved SUTENT as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.1,2